Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
16-week randomized open-label comparison of SIAC 30, SIAC 45, and NovoMix 30 plus metformin in type 2 diabetes
2007-002462-35Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2007
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of insulin degludec + insulin aspart, biphasic insulin aspart and metformin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: HbA1c after 16 weeks of treatment. Started Sep 2007; status: completed.
02
Drugs
insulin degludec + insulin aspartbiphasic insulin aspartmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-002462-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002462-35.